IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Examiner: Wollenberger, Louis V.

JOCKERS, et al.

Art Unit: 1635

Application No.: 10/774,721

Filed: February 9, 2004

Title: OLIGONUCLEOTIDES WHICH INHIBIT EXPRESSION OF THE OB-RGRP PROTEIN AND METHOD FOR DETECTING COMPOUNDS WHICH MODIFY THE INTERACTION BETWEEN PROTEINS OF THE OB-RGRP FAMILYAND THE LEPTIN

RECEPTOR

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in \$1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

\mathbf{X}	(b)	This	s Information Disclosure Statement is filed after the period set forth in 37 C.F.R.									
		1.97	97(b), but is believed to be filed before the mailing date of a final action under §1.1									
		or a	r a notice of allowance under §1.311, whichever occurs first.									
		(1)	The undersigned attorney certifies that each item of information contained in this									
			Information Disclosure Statement was cited in a communication from a foreign									
			patent office in a counterpart foreign application not more than three months prior									
			to the filing of this statement;									
		(2)	The undersigned attorney certifies that no item of information contained in this									
			Information Disclosure Statement was cited in a communication from a foreign									
			patent office in a counterpart foreign application or, to the knowledge of the									
			undersigned attorney after making reasonable inquiry, was known to any									
			individual designated in §1.56(c) more than three months prior to the filing of this									
			statement; or									
	\boxtimes	(3)	This Information Disclosure Statement is accompanied by a transmittal letter in									
			which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is									
			authorized.									

Respectfully submitted,

George S. Jones, Reg/No. 38,508 Attorney/Agent for Applicant

Sanofi-aventis
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3776
Telefax (908) 231-2626

Aventis Docket No. FRAV2003/0005 US NP

Please type a plus sign (+) inside this box 🗡 🗸							
	Please type :	a plus	sign (+)	inside	this box	→	7

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	te for form 1449A/PTO)		Complete if Known			
151=4		ь.		Application Number	10/774,721		
INF	JRMA HON	DI	SCLOSURE	Filing Date	02-09-2004		
STA	TEMENT B	Y	\PPLICANT	First Named Inventor	JOCKERS, ET AL		
				Group Art Unit	1635		
(use as many sheets es necessary)				Examiner Name	WOLLENBERGER, Louis V.		
Sheet	1	of	2	Attorney Docket Number	FRAV2003/0005 - US - NP		

				U.S. PATENT DOCU	JMENTS	
Examiner Initials	Cite No.1	U.S. Paten Number	t Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
			-			

					<u> </u>	
					_	
			-++			
			\rightarrow			
			\rightarrow			
					 	
					<u> </u>	
	Į.					

				FOR	IGN PATENT DOCUMENT	rs		
Examiner Initials	Cite No.1	Office ³	Foreign Patent Do Number ⁴	Cument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
						1		
		\vdash			······	ļ		┺
		 				ļ		₩.
		\vdash				1		+-
		l		- 		1		+
								\vdash

Examiner	Date	
Cianoturo	Considered	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

lease	type	a plus	sign (+)	inside	this	box	→	~

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
ollection of informetion unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons ere required to respond to a collection of information unless it contains a valid OMB control number

Substitu	te for form 1449B/PT	0		Complete if Known				
				Application Number	10/774,721			
INFO	DRMATIO	N D	ISCLOSURE	Filing Date	02-09-2004			
STA	TEMENT	RY	APPLICANT	First Named Inventor	JOCKERS			
• • • • • • • • • • • • • • • • • • • •			7.1. 1. 2.07.1111	Group Art Unit	1635			
	(use as many s	sheet	s as necessary)	Examiner Name	WOLLENBERGER, Louis V.			
Sheet	2	of	2	Attorney Docket Number	FRAV2003/0005 - US - NP			

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS										
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the erticle (when appropriate), title of the fitem (book, magazine, journal, serial, symposium, catalog, etc.), dete, page(s), volume-issue number(s), publisher, city and/or country where published.									
		HIDEO MAKIMURA et al., Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake, BMC Neuroscience (2002, pp. 1-6)								
- , -, ,,			<u> </u>							
	_		_							
			<u> </u>							
			-							
			 							

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the emount of time you are required to complete this form should be sent to the Chief Information Officer, Petent and Trademark Office, Weshington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



^{*}EXAMINER: Initial it reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation it not in conformance end not considered. Include copy of this form with next communication to epplicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.